ZBIO vs ARCT vs MRNA vs BNTX vs PFE

For growth investors, Zenas BioPharma, Inc.

(ZBIO) is the stronger pick with 100. 0% revenue growth year-over-year, versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). Pfizer Inc. (PFE) offers the better valuation at 19. 2x trailing P/E (8. 8x forward), making it the more compelling value choice. Analysts rate Zenas BioPharma, Inc. (ZBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zenas BioPharma, Inc.

(ZBIO) delivered a total return of -1. 2%, compared to -79. 7% for Arcturus Therapeutics Holdings Inc. (ARCT). Over 10 years, the gap is even starker: BNTX returned +550. 6% versus ARCT's -79. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 38β versus Arcturus Therapeutics Holdings Inc. 's 2. 46β — meaning ARCT is approximately 553% more volatile than PFE relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zenas BioPharma, Inc.

(ZBIO) is pulling ahead at 100. 0% versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). On earnings-per-share growth, the picture is similar: Moderna, Inc. grew EPS 21. 7% year-over-year, compared to -124. 5% for Zenas BioPharma, Inc.. Over a 3-year CAGR, PFE leads at -14. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -37. 8% for Zenas BioPharma, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -21. 1% for ZBIO. At the gross margin level — before operating expenses — ZBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARCT: 222.

8% to $22. 50.

In this comparison, PFE (6.

6% yield) pays a dividend. ZBIO, ARCT, MRNA, BNTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 38), 6. 6% yield). Arcturus Therapeutics Holdings Inc. (ARCT) carries a higher beta of 2. 46 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +25. 8%, ARCT: -79. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZBIO is a small-cap high-growth stock; ARCT is a small-cap quality compounder stock; MRNA is a mid-cap quality compounder stock; BNTX is a mid-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while ZBIO, ARCT, MRNA, BNTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.